Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
about
Screening for cervical cancer: when theory meets realityCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesAssessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic reviewDeriving effective vaccine allocation strategies for pandemic influenza: Comparison of an agent-based simulation and a compartmental model.Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission modelCost-effectiveness of different human papillomavirus vaccines in SingaporeHuman papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.Vaccine herd effect.Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.HPV vaccine acceptance, utilization and expected impacts in the U.S.: Where are we now?Human papilloma virus vaccination: impact and recommendations across the world.Health and economic implications of HPV vaccination in the United States.HPV vaccination among a community sample of young adult womenManagement strategies and cost effectiveness in the prevention of cervical cancer.Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women.Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening.Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets.Cost-effectiveness of human papillomavirus vaccination in the United StatesStructural differences among cost-effectiveness models of human papillomavirus vaccines.Model for assessing human papillomavirus vaccination strategies.Herd immunity: recent uses in vaccine assessment.Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.Type-specific human papillomavirus biological features: validated model-based estimatesTen years of anti-HPV vaccinations: what do we know?Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in IranEconomic evaluations of human papillomavirus vaccines.Cost–effectiveness of catch-up programs in human papillomavirus vaccination.Economic and humanistic burden of external genital warts.Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.Human Papillomavirus Vaccination Uptake in Canada: A Systematic Review and Meta-analysisThe HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions.Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness.Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.
P2860
Q21261292-6F1EC505-BA98-487E-ABF5-C58170B6DCF9Q24655328-C8E0C8DD-1E65-4BB3-A071-E5A65391C6DCQ28082953-A2135D0E-5232-4060-A6F0-DD10D71AA831Q30398939-F0C9B1BE-E639-4E31-9898-F768487B2D0EQ33327567-DA0D4276-E115-4053-B740-93BB327B4891Q33488325-245BA4E7-1FB4-4424-A1FF-213B12CC4D9AQ33859018-544DB101-D47F-4C54-8CE8-0B037C1389EFQ33898840-4F34A8DF-37E4-48FB-B670-4CB5C0A3312DQ33934529-0688BAE9-57F9-4E99-A432-0141A7D565B2Q34186752-D29AF0C6-7756-426D-AACD-DE4450EAC9EFQ34437088-B7CD1F14-6C70-4CF0-B664-B30D75047D57Q34440994-B686484A-E183-4A2A-B89D-9376939A6ECBQ34704575-5BFEAA81-327D-4528-ACBA-B2B78B1907EBQ34824304-1953FF88-099D-4F7A-A8C7-32C662624816Q35112562-2DCF7575-A41D-412F-96BA-7F09B0C2469BQ35205476-A51D1970-5C72-426F-95EE-418F87B2C0BBQ35484171-C2B45460-D1E6-44B5-BD74-F7D22CF60218Q36082663-02D413A1-7595-4666-9355-7F639C15D6AAQ36494175-F3C5BE07-53AF-42F2-9CB3-CE0DF66BD4A0Q36534239-9BC1E679-5A05-4F99-B6AB-2F3A5C66FE74Q36611500-3C8C6D6D-5504-49F6-8E53-C44E05C6C63CQ36983254-688EBA1C-6910-4650-9BF8-F00E68B3008BQ36999913-84F7C944-ED8B-43DC-A6BD-9B7AD24BCF32Q37009015-674E8266-A53F-4B99-9719-2B35E6EAACE0Q37259581-88C5968C-FF43-42E9-942C-BE3999C1F8A4Q37302509-5225C922-022A-4162-87CF-F5FD4BF36263Q37340454-3B2449FA-E6C6-406F-A0C9-A6E8EF9E5908Q37349884-6EF856E4-F150-4DB4-9D3F-5B07778808FBQ37439328-1B898431-522B-4AC8-9487-F546161D51C0Q37473145-16CFE49A-D7E7-4CB0-B524-E3A1EA5DBF6CQ37687207-448239D9-4D5C-4758-A91A-9952FC31FFC5Q37763114-D6A89CEF-6DAB-405C-944F-C981E88DA363Q37798010-31DB72EB-97C8-4C58-BD06-93B05FFCB139Q37971472-FF9512B7-CC30-4662-9745-161FCE1FC36CQ38027575-DC074C49-6406-4FC3-8019-23F3189DFC4DQ41923190-2628F5AB-95BD-466B-B980-F7FD32FBBFBFQ43697958-6A226D40-4E5B-49CC-8083-35D7C96B4E00Q44649838-6BFBFA5A-81F2-45BD-9CC6-C61BA261050FQ47100852-293EE245-E7D8-494C-AAB0-4D9622AC67B9Q47356408-F5AB81D9-0175-4B93-BC72-8AD994FCD89B
P2860
Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Mathematical models for predic ...... mavirus infection and disease.
@ast
Mathematical models for predic ...... mavirus infection and disease.
@en
type
label
Mathematical models for predic ...... mavirus infection and disease.
@ast
Mathematical models for predic ...... mavirus infection and disease.
@en
prefLabel
Mathematical models for predic ...... mavirus infection and disease.
@ast
Mathematical models for predic ...... mavirus infection and disease.
@en
P2093
P356
P1476
Mathematical models for predic ...... mavirus infection and disease.
@en
P2093
Elamin H Elbasha
Erik J Dasbach
Ralph P Insinga
P304
P356
10.1093/EPIREV/MXJ006
P577
2006-06-01T00:00:00Z